GSK said its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, raising hopes for a finite treatment course as an alternative to lifelong antiviral pills.
The British drugmaker presented detailed data from two studies of bepirovirsen on Thursday at a medical conference.
